The purpose of this Core is to provide the following services that will be utilized by the research projects included in this Program Project:
Specific Aim 1. To provide biostatistical collaboration for clinical research protocols. This includes all aspects of design, conduct, analysis and reporting of the clinical protocols, and direction of data processing and quality control assurance.
Specific Aim 2. To provide biostatistical collaboration for animal and laboratory research studies. This includes all aspects of design, conduct, analysis and reporting of such studies, including the coordination of laboratory results with parameters and outcomes from the clinical studies.
Specific Aim 3. To supervise the data processing and data quality assurance, and to coordinate the efforts of the data coordinator and those of the data analyst in maintaining an accurate computerized database.
Specific Aim 4. To provide computing resources for data processing, forms design, statistical analysis, standardized reporting and quality control.
Specific Aim 5. To provide bioinformatic support for analysis of high throughput transcriptional and genomic studies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA078378-14
Application #
8462449
Study Section
Special Emphasis Panel (ZCA1-RPRB-J)
Project Start
Project End
Budget Start
2013-04-01
Budget End
2014-03-31
Support Year
14
Fiscal Year
2013
Total Cost
$252,051
Indirect Cost
$115,541
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Hu, Y; Song, W; Cirstea, D et al. (2015) CSNK1?1 mediates malignant plasma cell survival. Leukemia 29:474-82
Bae, J; Prabhala, R; Voskertchian, A et al. (2015) A multiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T cells of smoldering myeloma patients. Leukemia 29:218-29
Suzuki, R; Hideshima, T; Mimura, N et al. (2015) Anti-tumor activities of selective HSP90?/? inhibitor, TAS-116, in combination with bortezomib in multiple myeloma. Leukemia 29:510-4
Tian, Ze; D'Arcy, Padraig; Wang, Xin et al. (2014) A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance. Blood 123:706-16
Campigotto, Federico; Weller, Edie (2014) Impact of informative censoring on the Kaplan-Meier estimate of progression-free survival in phase II clinical trials. J Clin Oncol 32:3068-74
Samur, Mehmet Kemal (2014) RTCGAToolbox: a new tool for exporting TCGA Firehose data. PLoS One 9:e106397
Cottini, Francesca; Hideshima, Teru; Xu, Chunxiao et al. (2014) Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers. Nat Med 20:599-606
Kronke, Jan; Udeshi, Namrata D; Narla, Anupama et al. (2014) Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 343:301-5
Hideshima, Hiromasa; Yoshida, Yasuhiro; Ikeda, Hiroshi et al. (2014) IKK? inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells. Int J Oncol 44:1171-6
Tai, Y-T; Landesman, Y; Acharya, C et al. (2014) CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia 28:155-65

Showing the most recent 10 out of 135 publications